Shandong Weigao Group Medical Polymer Insiders Sold CN¥8.2m Of Shares Suggesting Hesitancy
Shandong Weigao Group Medical Polymer Insiders Sold CN¥8.2m Of Shares Suggesting Hesitancy
The fact that multiple Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.
在过去的一年中,多位山东威高集团医用高分子股份有限公司(HKG: 1066)内部人士抛售了大量股票,这一事实可能会引起投资者的关注。在评估内幕交易时,了解内部人士是否在买入通常更有帮助,因为内幕卖出可能有多种解释。但是,股东应更深入地研究是否有几位内部人士在特定时间段内出售股票。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
虽然我们绝不会建议投资者仅根据公司董事的所作所为做出决定,但逻辑要求你应该注意内部人士是在买入还是卖出股票。
See our latest analysis for Shandong Weigao Group Medical Polymer
查看我们对山东威高集团医用聚合物的最新分析
Shandong Weigao Group Medical Polymer Insider Transactions Over The Last Year
山东威高集团医用聚合物去年内幕交易
Over the last year, we can see that the biggest insider sale was by the Executive Chairman of the Board & Compliance Officer, Jing Long, for HK$5.8m worth of shares, at about HK$12.04 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is HK$7.68. So it is hard to draw any strong conclusion from it.
在过去的一年中,我们可以看到,最大的内幕出售是董事会执行主席兼合规官龙景龙,以每股约12.04港元的价格出售了价值580万港元的股票。虽然我们通常不喜欢看到内幕抛售,但更令人担忧的是销售是否以较低的价格进行。令人欣慰的是,此次出售的价格远高于目前的股价,即7.68港元。因此,很难从中得出任何有力的结论。
In the last year Shandong Weigao Group Medical Polymer insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
去年,山东威高集团医用高分子内部人士没有购买任何公司股票。你可以在下面看到过去 12 个月内幕交易(由公司和个人进行的)的直观描述。如果你点击图表,你可以看到所有的个人交易,包括股价、个人和日期!
I will like Shandong Weigao Group Medical Polymer better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我看到一些大规模的内幕买入,我会更喜欢山东威高集团医用聚合物。在我们等待的同时,请查看这份免费名单,列出了最近有大量内幕买入的成长型公司。
Insider Ownership
内部所有权
Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 0.3% of Shandong Weigao Group Medical Polymer shares, worth about HK$90m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
许多投资者喜欢检查公司有多少股份由内部人士拥有。我认为,如果内部人士拥有该公司的大量股份,那将是一个好兆头。业内人士拥有山东威高集团医用聚合物0.3%的股份,价值约9000万港元。尽管这是内部人所有权强劲但并不突出的水平,但这足以表明管理层与小股东之间有一定的一致性。
What Might The Insider Transactions At Shandong Weigao Group Medical Polymer Tell Us?
山东威高集团医用聚合物的内幕交易可能告诉我们什么?
There haven't been any insider transactions in the last three months -- that doesn't mean much. Still, the insider transactions at Shandong Weigao Group Medical Polymer in the last 12 months are not very heartening. The modest level of insider ownership is, at least, some comfort. Of course, the future is what matters most. So if you are interested in Shandong Weigao Group Medical Polymer, you should check out this free report on analyst forecasts for the company.
在过去的三个月中,没有任何内幕交易——这并不意味着什么。尽管如此,山东威高集团医用高分子在过去12个月中的内幕交易并不令人鼓舞。内幕所有权的适度水平至少让人感到安慰。当然,未来是最重要的。因此,如果你对山东威高集团医用高分子感兴趣,你应该看看这份关于该公司分析师预测的免费报告。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你想看看另一家公司——一家财务状况可能优越的公司——那么千万不要错过这份免费的股本回报率高、债务低的有趣公司的名单。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。